Your browser is no longer supported. Please, upgrade your browser.
AEZS Aeterna Zentaris Inc. daily Stock Chart
Aeterna Zentaris Inc.
Index- P/E- EPS (ttm)-0.02 Insider Own0.60% Shs Outstand21.52M Perf Week0.87%
Market Cap27.00M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float23.28M Perf Month58.90%
Income-0.40M PEG- EPS next Q- Inst Own21.40% Short Float0.32% Perf Quarter48.66%
Sales1.60M P/S16.88 EPS this Y-240.50% Inst Trans4.62% Short Ratio0.19 Perf Half Y29.61%
Book/sh0.08 P/B14.50 EPS next Y- ROA-1.70% Target Price- Perf Year-58.72%
Cash/sh0.40 P/C2.94 EPS next 5Y- ROE23.50% 52W Range0.40 - 3.11 Perf YTD27.47%
Dividend- P/FCF- EPS past 5Y58.80% ROI628.40% 52W High-62.70% Beta1.98
Dividend %- Quick Ratio3.30 Sales past 5Y117.20% Gross Margin19.70% 52W Low192.75% ATR0.10
Employees11 Current Ratio3.50 Sales Q/Q2845.90% Oper. Margin- RSI (14)68.92 Volatility7.51% 11.71%
OptionableYes Debt/Eq0.18 EPS Q/Q111.90% Profit Margin-22.20% Rel Volume0.36 Prev Close1.14
ShortableYes LT Debt/Eq0.06 Earnings- Payout- Avg Volume399.87K Price1.16
Recom- SMA2011.62% SMA5039.92% SMA20010.93% Volume142,240 Change1.31%
Jul-19-17Reiterated Maxim Group Buy $2 → $4
May-10-17Reiterated H.C. Wainwright Buy $7.50 → $3
May-01-17Reiterated Maxim Group Buy $11 → $2
Jan-17-17Reiterated Maxim Group Buy $7 → $10
Dec-02-15Reiterated H.C. Wainwright Buy $11 → $12
Nov-24-15Reiterated H.C. Wainwright Buy $0.11 → $11
Nov-23-15Reiterated Maxim Group Buy $200 → $11
Apr-14-15Upgrade H.C. Wainwright Neutral → Buy $1.25
Nov-06-14Downgrade H.C. Wainwright Buy → Neutral
Jul-17-14Initiated H.C. Wainwright Buy $3
Jan-03-13Upgrade MLV & Co Hold → Buy $5.50
Oct-09-12Initiated Maxim Group Buy $9
Apr-02-12Downgrade MLV & Co Buy → Hold
Jun-07-11Initiated Oppenheimer Outperform $5.50
Apr-27-11Reiterated Canaccord Genuity Speculative Buy $2.75 → $4
Nov-29-10Initiated MLV Capital Buy $5.50
Feb-05-09Upgrade RBC Capital Mkts Sector Perform → Outperform
Jun-03-08Reiterated Canaccord Adams Buy $3.20 → $2.65
Apr-14-08Reiterated Canaccord Adams Buy $4.50 → $3.20
Oct-03-07Reiterated Rodman & Renshaw Mkt Outperform $8 → $6
May-15-20 04:45PM  
May-08-20 09:00AM  
May-06-20 08:05AM  
May-03-20 07:30PM  
Apr-30-20 03:08PM  
Apr-15-20 04:06PM  
Apr-07-20 01:00PM  
Apr-06-20 09:00AM  
Apr-03-20 10:36AM  
Mar-30-20 05:00PM  
Mar-12-20 08:00AM  
Feb-21-20 02:00PM  
Feb-20-20 07:06AM  
Feb-19-20 07:00PM  
Feb-12-20 08:05AM  
Jan-28-20 08:00AM  
Jan-27-20 08:35AM  
Jan-09-20 08:39AM  
Jan-08-20 04:01PM  
Dec-30-19 06:38AM  
Dec-20-19 05:45PM  
Dec-18-19 09:00AM  
Dec-16-19 09:00AM  
Nov-07-19 06:28PM  
Nov-05-19 07:56AM  
Oct-29-19 10:33AM  
Oct-08-19 09:00AM  
Oct-04-19 04:59PM  
Sep-26-19 06:34AM  
Sep-24-19 04:01PM  
Sep-20-19 11:00AM  
Aug-20-19 11:16PM  
Aug-13-19 05:45PM  
Aug-01-19 10:33AM  
Jul-01-19 10:30AM  
Jun-06-19 02:06PM  
May-08-19 06:04PM  
May-07-19 07:25PM  
May-02-19 10:02AM  
Apr-29-19 10:31AM  
Mar-26-19 07:50PM  
Mar-19-19 08:00AM  
Mar-18-19 11:18AM  
Mar-13-19 07:27AM  
Mar-12-19 04:32PM  
Mar-04-19 08:58AM  
Feb-27-19 09:57AM  
Feb-26-19 08:55AM  
Feb-14-19 10:45AM  
Feb-13-19 08:36AM  
Jan-29-19 09:30AM  
Jan-16-19 09:03AM  
Jan-09-19 09:50AM  
Jan-07-19 09:30AM  
Dec-24-18 05:50PM  
Dec-21-18 05:04PM  
Dec-20-18 09:30AM  
Dec-17-18 05:50PM  
Dec-07-18 05:45PM  
Dec-04-18 12:51PM  
Nov-30-18 05:41AM  
Nov-19-18 09:00AM  
Nov-16-18 10:50AM  
Nov-06-18 07:54PM  
Nov-01-18 08:20AM  
Oct-31-18 04:05PM  
Sep-25-18 08:00AM  
Aug-10-18 07:27AM  
Aug-09-18 06:57PM  
Aug-02-18 04:05PM  
May-31-18 04:15PM  
May-29-18 08:44AM  
May-25-18 08:44AM  
May-24-18 08:46AM  
May-16-18 08:45AM  
May-14-18 02:10PM  
May-11-18 09:24AM  
May-08-18 04:15PM  
May-07-18 06:41PM  
May-01-18 05:05PM  
Apr-19-18 07:20AM  
Apr-09-18 08:00AM  
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology and endocrinology. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications. The company has a license and assignment agreement with Strongbridge Ireland Limited for the development, manufacturing, registration, and commercialization of Macrilen in the United States and Canada. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.